ライフサイエンスコーパス: week thereafter

1 simultaneously with challenging nymphs and 1 week thereafter.

2 100 mg, and 200 mg, then 400 mg daily for 1 week], thereafter continuing at 400 mg daily until compl

3 d six HIV-1LAI envelope immunizations and 10 weeks thereafter acquired HIV-1 infection through a high

4 acebo every 4 weeks for 7 doses and every 12 weeks thereafter until a treatment discontinuation crite

5 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuation.

6 seline, weeks 4, 7, 10, and 24, and every 12 weeks thereafter up to 2 years, irrespective of disease

7 eks, or 200 mg at weeks 0 and 4 and every 12 weeks thereafter) through week 40, placebo, or adalimuma

8 attendance at week 4, week 12, and every 12 weeks thereafter), refills, self-reported adherence up t

9 8 weeks, 50 mg at weeks 0 and 4 and every 12 weeks thereafter, 100 mg every 8 weeks, or 200 mg at wee

10 selkumab (5 mg at weeks 0 and 4 and every 12 weeks thereafter, 15 mg every 8 weeks, 50 mg at weeks 0

11 8 weeks for the first 6 months and every 12 weeks thereafter.

12 pulation, assessed at screening and every 12 weeks thereafter.

13 ery 6 weeks up to week 48, and then every 12 weeks thereafter.

14 treatment from day 1 of cycle 1 and every 12 weeks thereafter.

15 which they continued at week 28 and every 12 weeks thereafter.

16 , or placebo at week 0, week 4, and every 12 weeks thereafter.

17 baseline (b; n = 472), week 9, and every 12 weeks thereafter.

18 1.1 every 6 weeks for 12 months and every 12 weeks thereafter; the secondary end point was safety.

19 ionnaires at baseline, week 17, and every 16 weeks thereafter until treatment discontinuation.

20 y an escalation to 100 mg twice daily for 18 weeks thereafter.

21 uring leaf flush and did not vary for the 19 weeks thereafter when leaves remained active.

22 orming units/mL), then in week 4 and every 2 weeks thereafter (10(8) plaque-forming units/mL).

23 n day 22 (cycle 2), and 10(8) PFU/mL every 2 weeks thereafter (cycles 3).

24 se), and 7 (full dose) and then once every 2 weeks thereafter for 20 weeks.

25 t 6-8 weeks of age (pre-plaque), and every 2 weeks thereafter until all mice were at least 16 weeks o

26 t week 1, 80 mg at week 2, and 40 mg every 2 weeks thereafter until week 50 (plus infusions of placeb

27 th, and meetings with the study team every 2 weeks thereafter, for the duration of the circumcision c

28 ting 1-week post-hospitalization and every 2 weeks thereafter.

29 ed measures before randomization and every 2 weeks thereafter.

30 and 3 infusions of 250 million cells every 2 weeks thereafter; total infusion period, 50 days).

31 rtical contusion and persists for at least 2 weeks thereafter.

32 ays without significant changes during the 2 weeks thereafter.

33 nd followed up at weeks 12, 24, and every 24 weeks thereafter in a multicenter longitudinal cohort st

34 at baseline, week 12, week 24, and every 24 weeks thereafter, and potential cases of new-onset diabe

35 ent for 48 weeks and were followed up for 24 weeks thereafter.

36 h a single high dose of streptozotocin and 3 weeks thereafter used as oocyte donors for in vitro fert

37 efore treatment (bIgE) with omalizumab and 4 weeks thereafter (w4IgE).

38 -2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter (28-day cycles) until progressive disea

39 d by 1 week of rest, then weekly x 3 every 4 weeks thereafter (63 patients), or to fluorouracil (5-FU

40 for 16 weeks (cycles 3-6), and then every 4 weeks thereafter (cycle 7 and higher).

41 in cycles two through nine, and once every 4 weeks thereafter as maintenance therapy until disease pr

42 every 2 weeks in cycles 3 to 6, and every 4 weeks thereafter for up to 2 years.

43 every 2 weeks during cycles 3-6, and every 4 weeks thereafter until disease progression or unacceptab

44 3, every 2 weeks for cycles 4-9, and every 4 weeks thereafter until disease progression or unacceptab

45 very 3 weeks in cycles 2-9, and once every 4 weeks thereafter until disease progression, unacceptably

46 every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxic

47 kg) or placebo at weeks 0, 2, 4, and every 4 weeks thereafter until week 24.

48 ntramuscularly at weeks 0, 2, 4, and every 4 weeks thereafter until week 44.

49 stered at weeks 0, 2, and 4 and then every 4 weeks thereafter with the last dose at week 20.

50 very 2 weeks in cycles 3-6, and once every 4 weeks thereafter) plus oral lenalidomide (25 mg on days

51 owed by 250 mg on days 15 and 28 and every 4 weeks thereafter, and either lapatinib 1,500 mg or place

52 ived 2 mg of IVT-AFL at baseline and every 4 weeks thereafter, until disease stability criteria were

53 ks for four cycles (cycles 3-6), and every 4 weeks thereafter.

54 erence were measured at baseline and every 4 weeks thereafter.

55 ds) will be measured at baseline and every 4 weeks thereafter.

56 10 mg/kg) on days 1, 15, and 29 and every 4 weeks thereafter.

57 were at baseline, weeks 2 and 4, and every 4 weeks thereafter.

58 00 mg on days 1, 15, and 29 and once every 4 weeks thereafter.

59 were scanned at 1 month of life and every 4 weeks thereafter.

60 subcutaneously at weeks 0, 2, 4, and every 4 weeks thereafter.

61 -2), every 2 weeks (cycles 3-6), and every 4 weeks thereafter.

62 weeks for the first 3 infusions and every 4 weeks thereafter.

63 n every other week for 16 weeks, and every 4 weeks thereafter; carfilzomib 56 mg/m(2) intravenously o

64 ty was assessed at weeks 2 and 4 and every 4 weeks thereafter; tumor response was evaluated every 8 t

65 placebo for 2 weeks and were followed for 4 weeks thereafter.

66 ed estrogen therapy and every 6 weeks for 48 weeks thereafter.

67 c tumors (MIA PaCa-2) were subsequently (4-5 weeks thereafter) injected with saline (control), gemcit

68 were repeated at 4 and 8 weeks, and every 5 weeks thereafter.

69 , and follow-up images were acquired every 6 weeks thereafter until tumor progression or death.

70 re assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation for Res

71 tion (baseline) and at 1 day, 4 weeks, and 8 weeks thereafter.

72 ss response at 6 weeks, 20 weeks and every 8 weeks thereafter and tolerability of the combined treatm

73 were given at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46.

74 infusions at weeks 0, 2, and 6, and every 8 weeks thereafter through week 52 at tertiary centers in

75 of placebo at weeks 2 and 6 and then every 8 weeks thereafter until week 46 (group I), repeat infusio

76 0 mg, at weeks 0, 2, and 6, and then every 8 weeks thereafter) induces endoscopic, radiologic, and hi

77 nistered at one 4 week interval, and every 8 weeks thereafter) or placebo.

78 usly) at weeks 0, 2, and 6, and then every 8 weeks thereafter, for 26 weeks (primary study) or 52 wee

79 reatment was assessed at week 12 and every 8 weeks thereafter.

80 eight) at weeks 1, 3, 7, and 14, and every 8 weeks thereafter.

81 to 21 weeks after randomisation, and every 8 weeks thereafter.

82 re obtained routinely at 4 weeks and every 8 weeks thereafter.

83 ntramuscularly at weeks 4 and 8, and every 8 weeks thereafter.

84 ry 4 weeks for the first 3 doses and every 8 weeks thereafter.

85 ons of the same dose were given every 4 or 8 weeks thereafter on a background of a stable dose of met

86 iweekly from weeks 4 to 12, and every 4 to 8 weeks thereafter.

87 sual acuity protocol at baseline and every 9 weeks thereafter until no further improvement in visual

88 ere assessed at day 1 of cycles 1-3, every 9 weeks thereafter, at the treatment discontinuation visit

89 sed every 6 weeks until month 18 and every 9 weeks thereafter.

90 initial dose 400 mg/m(2); 250 mg/m(2) once a week thereafter).

91 Eight weeks thereafter, a postmortem examination was performed

92 ber of animals died at birth or within a few weeks thereafter.

93 One week thereafter, the MI+CSD group and 10 animals without

94 then 40 mg at weeks 1, 3, 5, and every other week thereafter during a 16-week double-blind treatment

95 e first 2 years of treatment and 20 U/m2 per week thereafter, 3 untreated children were lost to long-

96 160 days and by a mean of 1.9 cells/mm3 per week thereafter (P < 0.01).

97 per week for the first 24 weeks and once per week thereafter) and dexamethasone (20 mg four times per

98 er week for the first 24 weeks and twice per week thereafter).

99 mg at week 4; and 1200 mg given every second week thereafter as maintenance dosing.

100 Six weeks thereafter, 2 of 5 animals were given an intraderm

101 e in an experience-dependent manner for some weeks thereafter.

102 onset, followed by a gradual decline in the weeks thereafter.

103 Two weeks thereafter, ovariectomized and proestrus sham-ovar

104 ardiac-transplantation surgery and every two weeks thereafter, for a total of five doses, or generali